JPRN-UMIN000011449招募中未知
Clinical efficacy in the budesonide / folmoterol for the COPD patients under using tiotropium. - Clinical efficacy in the budesonide / folmoterol for the COPD patients under using tiotropium.
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(a) The patient who has BUD/FM in preliminary medication (b) The patient who has received hospitalization or the whole body, inhalation steroid medicine medication, and medication of the antibiotic within one month before the examination (c) The patient who has received the domiciliary oxygen therapy periodically (d) A patient with the past of bronchial asthma (e) The patient who has the past of hypersensitivity in BUD/FM (f) The patient who has chronic diseases, such as a lung, the heart, the kidney, liver, and blood (g) The patient who has an anamnesis of adrenal cortical insufficiency (h) The patient who judged test inclusion to be improper by an examination responsibility doctor's judgment
研究者
相似试验
已完成
不适用
Clinical effects of budesonide/formoterol in patients with asthmaBronchial asthmaJPRN-UMIN000003745Atami Hospital International University of Health and Welfare30
招募中
不适用
The clinical study of the budesonide/formoterol combination drug additional dosage in the perioperative period in a lung cancer patient with COPD.on-small cell lung cancer patients with COPD.JPRN-UMIN000011462Hamamatsu University School of Medicine40
已完成
不适用
Efficacy and safety of budesonide /formeterol inhalation in asthma patients with high fractional exhaled NO.Bronchial asthmaJPRN-UMIN000003735Komaki City Hospital20
已完成
不适用
Efficacy and safety of budesonide/formoterol in patients with mild to moderate persistent asthmabronchial asthmaJPRN-UMIN000004465ESCORT Study Group200
已完成
不适用
Study on the effects of the budesonide/formoterol combination formulation in improving airway inflammation and airway resistance in patients with bronchial asthmaPatients with bronchial asthma aged 20 years and older (males and females, outpatients and inpatients) being treated with an ICS (at a dose equivalent to FP 200-1000 mcg/day) and salmeterol 100 mcg/day in combination (either as two separate products or one combined product) for 3 months or longer with poor or inadequate controlJPRN-UMIN000006572Chiba-Hokusoh Hospital, Nippon Medical School80